Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), granting Fosun exclusive promotion and marketing rights to Amoytop’s pegfilgrastim (Y shape) in mainland China. As part of the deal, Fosun is paying RMB 63 million (USD 8.9 million) upfront and is also committed to future milestone payments, in addition to a promotion service fee.
Pegfilgrastim (Y shape): A Category 1 Biologic Product
Pegfilgrastim (Y shape) is a Category 1 biologic product developed in-house by Amoytop Biotech. It is a long-acting human granulocyte stimulating factor currently awaiting regulatory decisions in China for use in patients with non-myeloid malignancies who receive bone marrow suppressive anticancer drugs that can easily cause febrile neutropenia. The drug is designed to reduce the incidence of infections manifested as febrile neutropenia. The product features a 40kD Y-branch polyethylene glycol (PEG) molecule to modify human granulocyte stimulating factor, offering a longer half-life and a lower drug dose than similar products on the market.
Commercialization Rights and Sublicense Deal
In a reciprocal agreement, Fosun has granted Amoytop commercialization rights to the 1mg specification of the product in the assisted reproduction field, under an initially 7-year-sublicense deal. This strategic partnership leverages the strengths of both companies, expanding the reach of pegfilgrastim (Y shape) in the Chinese market and potentially improving patient outcomes in the treatment of febrile neutropenia and assisted reproduction.-Fineline Info & Tech
